Chris Shibutani
Stock Analyst at Goldman Sachs
(3.54)
# 840
Out of 5,154 analysts
94
Total ratings
55.1%
Success rate
21.86%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $58.25 | +71.67% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $15.54 | -80.69% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $9.52 | +57.56% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.35 | +12.87% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $101.95 | +34.38% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.58 | +52.92% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $485.06 | -37.74% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $45.68 | +11.65% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $239.63 | -35.32% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $14.10 | -71.63% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $6.71 | +198.06% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $983.26 | -26.47% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $13.03 | +99.54% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $129.64 | +18.02% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $232.35 | -25.54% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $72.45 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $60.74 | +13.60% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $22.18 | -41.39% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $99.64 | -76.92% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $83.52 | -37.74% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.61 | +125.48% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.62 | +54.91% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $16.83 | +1.01% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.27 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.23 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $58.25
Upside: +71.67%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $15.54
Upside: -80.69%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $9.52
Upside: +57.56%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.35
Upside: +12.87%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $101.95
Upside: +34.38%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.58
Upside: +52.92%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $485.06
Upside: -37.74%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $45.68
Upside: +11.65%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $239.63
Upside: -35.32%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $14.10
Upside: -71.63%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $6.71
Upside: +198.06%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $983.26
Upside: -26.47%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $13.03
Upside: +99.54%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $129.64
Upside: +18.02%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $232.35
Upside: -25.54%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $72.45
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $60.74
Upside: +13.60%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $22.18
Upside: -41.39%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $99.64
Upside: -76.92%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $83.52
Upside: -37.74%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.61
Upside: +125.48%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.62
Upside: +54.91%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $16.83
Upside: +1.01%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.27
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.23
Upside: -